ValiRx PLC Exercise of Warrants (3870X)
August 28 2020 - 2:00AM
UK Regulatory
TIDMVAL
RNS Number : 3870X
ValiRx PLC
28 August 2020
VALIRX PLC
("ValiRx", the "Company" or the "Group")
Exercise of Warrants
London, UK 28 August 2020: ValiRx Plc (AIM: VAL), the clinical
stage biotechnology company announces it has received notification
for the exercise of a warrant over 250,000 ordinary shares in the
Company at an exercise price of 12.5 pence per share providing the
Company with proceeds of GBP31,250 ("Warrant Exercise").
The Company has also received notifications for the exercise of
warrants pursuant to the Fundraise Warrants announced on 4 May 2020
in relation to the fundraise at the time. The Company has received,
in aggregate, exercise of warrants over 2,791,666 ordinary shares
at an exercise price of 13 pence per share providing the Company
with aggregate proceeds of GBP362,916. The Company has previously
applied to list these shares as part of the block listing of
9,034,734 ordinary shares of 0.1 pence each in the Company
(announced on 19 August 2020), which were admitted to trading on
AIM on 24 August 2020.
Application will be made to the London Stock Exchange to admit
the 250,000 new ordinary shares resulting from the Warrant Exercise
to trading on AIM. Admission of the new ordinary shares is expected
to occur on or around 3 September 2020. The new ordinary shares
will rank pari passu with the existing ordinary shares.
For the purposes of the Disclosure and Transparency Rules,
following the issue of shares detailed above as a result of the
Warrant Exercise and the exercise of 2,791,666 warrants pursuant to
the ValiRx plc Fundraise Warrants May 2020 block listing
application announced on 19 August 2020, the enlarged issued share
capital of the Company will comprise 57,104,039 ordinary shares of
0.1 pence each. The Company does not hold any shares in treasury.
The above figure may be used by shareholders as the denominator for
the calculations by which they will determine if they are required
to notify their interest in, or a change to their interest in, the
Company, under the Disclosure and Transparency Rules.
A Total Voting Rights announcement will be released by the
Company on 1 September 2020.
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For further information please contact:
ValiRx plc Tel: +44 (0) 20 7073
2628
www.valirx.com
Suzanne Dilly Suzanne.Dilly@valirx.com
Cairn Financial Advisers LLP (Nominated Tel: +44 (0) 20 7213
Adviser) 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
Peterhouse Capital Limited (Sole Broker) Tel: +44 (0) 20 7469
Duncan Vasey / Lucy Williams / Eran Zucker 0930
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCPRMPTMTBTBPM
(END) Dow Jones Newswires
August 28, 2020 02:00 ET (06:00 GMT)
Valirx (LSE:VAL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Valirx (LSE:VAL)
Historical Stock Chart
From Apr 2023 to Apr 2024